Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Novel plant-specific cyclin-dependent kinase inhibitors induced by biotic and abiotic stresses.

Peres A, Churchman ML, Hariharan S, Himanen K, Verkest A, Vandepoele K, Magyar Z, Hatzfeld Y, Van Der Schueren E, Beemster GT, Frankard V, Larkin JC, Inzé D, De Veylder L.

J Biol Chem. 2007 Aug 31;282(35):25588-96. Epub 2007 Jun 28.

2.

Arabidopsis WEE1 kinase controls cell cycle arrest in response to activation of the DNA integrity checkpoint.

De Schutter K, Joubès J, Cools T, Verkest A, Corellou F, Babiychuk E, Van Der Schueren E, Beeckman T, Kushnir S, Inzé D, De Veylder L.

Plant Cell. 2007 Jan;19(1):211-25. Epub 2007 Jan 5.

3.

Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours.

Lambin P, Theys J, Landuyt W, Rijken P, van der Kogel A, van der Schueren E, Hodgkiss R, Fowler J, Nuyts S, de Bruijn E, Van Mellaert L, Anné J.

Anaerobe. 1998 Aug;4(4):183-8.

PMID:
16887640
4.

The cyclin-dependent kinase inhibitor KRP2 controls the onset of the endoreduplication cycle during Arabidopsis leaf development through inhibition of mitotic CDKA;1 kinase complexes.

Verkest A, Manes CL, Vercruysse S, Maes S, Van Der Schueren E, Beeckman T, Genschik P, Kuiper M, Inzé D, De Veylder L.

Plant Cell. 2005 Jun;17(6):1723-36. Epub 2005 Apr 29.

5.

The plant-specific cyclin-dependent kinase CDKB1;1 and transcription factor E2Fa-DPa control the balance of mitotically dividing and endoreduplicating cells in Arabidopsis.

Boudolf V, Vlieghe K, Beemster GT, Magyar Z, Torres Acosta JA, Maes S, Van Der Schueren E, Inzé D, De Veylder L.

Plant Cell. 2004 Oct;16(10):2683-92. Epub 2004 Sep 17.

6.

The Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC): a critical appraisal of 20 years of continuous efforts.

Kouloulias VE, Poortmans PM, Bernier J, Horiot JC, Johansson KA, Davis B, Godson F, Garavaglia G, Pierart M, van der Schueren E.

Eur J Cancer. 2003 Mar;39(4):430-7. Review.

PMID:
12751372
7.

Control of proliferation, endoreduplication and differentiation by the Arabidopsis E2Fa-DPa transcription factor.

De Veylder L, Beeckman T, Beemster GT, de Almeida Engler J, Ormenese S, Maes S, Naudts M, Van Der Schueren E, Jacqmard A, Engler G, Inzé D.

EMBO J. 2002 Mar 15;21(6):1360-8.

8.

Functional analysis of cyclin-dependent kinase inhibitors of Arabidopsis.

De Veylder L, Beeckman T, Beemster GT, Krols L, Terras F, Landrieu I, van der Schueren E, Maes S, Naudts M, Inzé D.

Plant Cell. 2001 Jul;13(7):1653-68.

9.

Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging.

Weltens C, Menten J, Feron M, Bellon E, Demaerel P, Maes F, Van den Bogaert W, van der Schueren E.

Radiother Oncol. 2001 Jul;60(1):49-59.

PMID:
11410304
10.

Arabidopsis thaliana genes expressed in the early compatible interaction with root-knot nematodes.

Vercauteren I, Van Der Schueren E, Van Montagu M, Gheysen G.

Mol Plant Microbe Interact. 2001 Mar;14(3):288-99.

11.

Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.

van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van Zijl K, Bartelink H.

J Natl Cancer Inst. 2000 Jul 19;92(14):1143-50.

PMID:
10904087
12.

Clinical radiation doses for spinal cord: the 1998 international questionnaire.

Fowler JF, Bentzen SM, Bond SJ, Ang KK, van der Kogel AJ, van den Bogaert W, van der Schueren E.

Radiother Oncol. 2000 Jun;55(3):295-300.

PMID:
10869744
13.

Improved management of radiotherapy departments through accurate cost data.

Kesteloot K, Lievens Y, van der Schueren E.

Radiother Oncol. 2000 Jun;55(3):251-62.

PMID:
10869740
14.

FECS Clinical Award lecture 1989. Factors in decision making in the treatment of breast cancer. Federation of European Cancer Societies.

van der Schueren E.

Radiother Oncol. 2000 Jun;55(3):205-16;discussion 217-8. No abstract available.

PMID:
10869736
16.

Radiation dose homogeneity in an EORTC multicenter trial on breast irradiation.

Ptaszynski AM, Van den Bogaert W, Horiot JC, Poortmans P, Fourquet A, Struikmans H, Bartelink H, Pierart M, Collette L, van der Schueren E.

Acta Oncol. 1999;38 Suppl 13:19-27.

PMID:
10612492
17.

The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.

Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M, Van der Schueren E, Bartelink H.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85.

PMID:
10524422
18.

Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.

Vrieling C, Collette L, Bartelink E, Borger JH, Brenninkmeyer SJ, Horiot JC, Pierart M, Poortmans PM, Struikmans H, Van der Schueren E, Van Dongen JA, Van Limbergen E, Bartelink H.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):667-76.

PMID:
10524421
19.

Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.

van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, Sylvester R, Fentiman IS, van der Schueren E, van Zijl K, Blichert-Toft M, Bartelink H, van Dongen JA.

Eur J Cancer. 1999 Jan;35(1):32-8.

PMID:
10211085
20.

Assessment of dose inhomogeneities in clinical practice by film dosimetry.

Weltens C, Huyskens D, Dutreix A, van der Schueren E.

Radiother Oncol. 1998 Dec;49(3):287-94.

PMID:
10075262
21.

A quality assurance network in Central European countries--radiotherapy infrastructure.

Novotny J, Izewska J, Dutreix A, van der Schueren E.

Acta Oncol. 1998;37(2):159-65.

PMID:
9636010
22.

Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.

Vansteenkiste JF, De Leyn PR, Deneffe GJ, Lievens YN, Nackaerts KL, Van Raemdonck DE, van der Schueren E, Lerut TE, Demedts MG.

Ann Oncol. 1998 Mar;9(3):261-7.

PMID:
9602259
23.

Identical cis-acting elements and related trans-acting factors control activity of nonviral promoter in Schizosaccharomyces pombe and mammalian cells.

Brys R, Nelles L, van der Schueren E, Silvestre N, Huylebroeck D, Remacle JE.

DNA Cell Biol. 1998 Apr;17(4):349-58.

PMID:
9570152
24.

Chronic lymphocytic alveolitis with migrating pulmonary infiltrates after localized chest wall irradiation.

Van Haecke P, Vansteenkiste J, Paridaens R, Van der Schueren E, Demedts M.

Acta Clin Belg. 1998 Feb;53(1):39-43.

PMID:
9562704
25.

Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: Is it worthwhile to measure Tpot?

Haustermans K, Fowler J, Geboes K, Christiaens MR, Lerut A, van der Schueren E.

Radiother Oncol. 1998 Feb;46(2):157-67.

PMID:
9510043
26.

Kinetics of repair in the spinal cord of the rat.

Landuyt W, Fowler J, Ruifrok A, Stüben G, van der Kogel A, van der Schueren E.

Radiother Oncol. 1997 Oct;45(1):55-62.

PMID:
9364632
27.

Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate?

Haustermans K, Fowler J, Landuyt W, Lambin P, van der Kogel A, van der Schueren E.

Radiother Oncol. 1997 Oct;45(1):39-47.

PMID:
9364630
28.

Do cell kinetics have prognostic and/or predictive value in oesophageal cancer treated by surgery?

Haustermans K, Fowler F, Geboes K, Lerut T, van der Schueren E.

Eur J Surg Oncol. 1997 Aug;23(4):293-7.

PMID:
9315055
29.

Biological equivalance of low dose rate to multifractionated high dose rate irradiations: investigations in mouse lip mucosa.

Stüben G, van der Kogel AJ, van der Schueren E.

Radiother Oncol. 1997 Feb;42(2):189-96.

PMID:
9106929
30.
31.

Enrichment of tumor cells for cell kinetic analysis in human tumor biopsies using cytokeratin gating.

Haustermans K, Hofland I, Ramaekers M, Ivanyi D, Balm AJ, Geboes K, Lerut T, van der Schueren E, Begg AC.

Radiother Oncol. 1996 Dec;41(3):237-48.

PMID:
9027940
32.

Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study.

Tomiak E, Piccart M, Mignolet F, Sahmoud T, Paridaens R, Nooy M, Beex L, Fentiman IS, Muller A, van der Schueren E, Rubens RD.

Eur J Cancer. 1996 Oct;32A(11):1876-87.

PMID:
8943669
33.

The time course of development of late side effects after irradiation of the prostate with multiple fractions per day.

Lievens Y, Vanuytsel L, Rijnders A, Van Poppel H, van der Schueren E.

Radiother Oncol. 1996 Aug;40(2):147-52.

PMID:
8884968
34.

More detailed documentation of operative procedures in breast conserving treatment: what good will it do us?

Christiaens MR, van der Schueren E, Vantongelen K.

Eur J Surg Oncol. 1996 Aug;22(4):326-30. Review.

PMID:
8783645
35.

Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.

Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA.

Bone Marrow Transplant. 1996 May;17(5):745-51.

PMID:
8733692
36.

The influence of the IAEA standard holder on dose evaluated from TLD samples.

Izewska J, Novotny J, Van Dam J, Dutreix A, van der Schueren E.

Phys Med Biol. 1996 Mar;41(3):465-73.

PMID:
8778826
37.

Reimbursement for radiotherapy treatment in the EU countries: how to encourage efficiency, quality and access?

Kesteloot K, Pocceschi S, van der Schueren E.

Radiother Oncol. 1996 Mar;38(3):187-94.

PMID:
8693098
38.

Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer?

Van den Bogaert W, Van der Leest A, Rijnders A, Delaere P, Thames H, van der Schueren E.

Radiother Oncol. 1995 Sep;36(3):177-82.

PMID:
8532903
39.

The reimbursement of the expenses for medical treatment received by 'transnational' patients in EU-countries.

Kesteloot K, Pocceschi S, van der Schueren E.

Health Policy. 1995 Jul;33(1):43-57.

PMID:
10172359
40.

The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.

Van den Bogaert W, van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, de Pauw M, Van Glabbeke M.

Radiother Oncol. 1995 May;35(2):91-9.

PMID:
7569030
41.

The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.

Van den Bogaert W, van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, de Pauw M, van Glabbeke M.

Radiother Oncol. 1995 May;35(2):100-6.

PMID:
7569017
42.

Surgery for breast cancer.

Van den Bogaert W, van der Schueren E.

N Engl J Med. 1995 Jan 5;332(1):64. No abstract available.

PMID:
7990882
43.

Quality assurance network in central Europe. External audit on output calibration for photon beams.

Izewska J, Novotny J, Gwiazdowska B, Kindlova A, Kontra G, van Dam J, Dutreix A, van der Schueren E.

Acta Oncol. 1995;34(6):829-38.

PMID:
7576752
44.

Role of nurses in cancer chemotherapy administration. Retrospective record analysis to improve role performance.

Tanghe A, Evers G, Vantongelen K, Paridaens R, Van der Schueren E, Aerts R, Lejeune M, Vermeiren P.

Eur J Cancer Care (Engl). 1994 Dec;3(4):169-74.

PMID:
7704352
45.

Quality control of radiotherapy centres in Europe: beam calibration.

Dutreix A, Derreumaux S, Chavaudra J, van der Schueren E.

Radiother Oncol. 1994 Sep;32(3):256-64.

PMID:
7816944
46.

Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study.

González DG, Menten J, Bosch DA, van der Schueren E, Troost D, Hulshof MC, Bernier J.

Radiother Oncol. 1994 Aug;32(2):98-105.

PMID:
7972915
47.

A cost comparison of the use of fixed versus non-fixed versus individualised shielding blocks in radiotherapy.

Kesteloot K, Louwet G, Vande Velde G, van der Schueren E.

Radiother Oncol. 1994 May;31(2):151-60.

PMID:
8066194
48.

Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation tolerance.

Haustermans K, van der Kogel AJ, Vanacker B, van der Schueren E.

Radiother Oncol. 1994 May;31(2):123-8.

PMID:
8066191
49.

Reliability of clinical port films for measuring dose inhomogeneities in radiotherapy for head and neck tumours.

Weltens C, van Dam J, Leunens G, Dutreix A, van der Schueren E.

Radiother Oncol. 1994 Feb;30(2):167-70.

PMID:
8184116
50.

Importance of in vivo dosimetry as part of a quality assurance program in tangential breast treatments.

Leunens G, Van Dam J, Dutreix A, Van der Schueren E.

Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):285-96.

PMID:
8270453

Supplemental Content

Loading ...
Support Center